Brian Caveney, M.D., J.D., M.P.H.

EVP and President, Early Development Research Laboratories

Brian Caveney, M.D. has served as Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer at Labcorp since 2023.

In his current role, Brian leads all early development research laboratories globally and oversees all medical and scientific affairs, oncology, cell and gene therapy, and quality for Labcorp.

Anita Graham

Anita Graham has served as Executive Vice President and Chief Human Resources Officer since 2023.

Amy Summy

Amy Summy has served as Executive Vice President and Chief Marketing Officer since March 2020.

Adam Schechter

Global business leader Adam Schechter became Chief Executive Officer of Labcorp in November 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director in January 2019 after serving as a director of the company since 2013.

2024 Developments in Cardiometabolic Care for the Busy Primary Care Physician

The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.

Navigating the nontraditional: A look into fertility challenges and novel referral indications

Hear our subject matter experts share fertility-focused case studies that highlight the challenges and available options for nontraditional families, novel referral indications and how genetic counselors can support patients.

Society for Immunotherapy of Cancer (SITC 2024)

Antibody-drug conjugate (ADC): Navigating complex cancer therapy development

Support with developing an ADC targeted chemotherapy and CDx enabled a sponsor to navigate therapy complexity, global trial design and patient selection for a breakthrough cancer treatment.

nAbCyte™ CDx: One-time treatment. Zero room for error.

An estimated 6,000 people in the United States live with hemophilia B. nAbCyte™—the first CDx for a cell-based gene therapy—offers new hope for treatment. 

pTau217: Providing critical Alzheimer's diagnosis with key biomarker data

Every 3.2 seconds, someone globally is diagnosed with Alzheimer’s. pTau217—Labcorp’s simple and highly accurate blood-based test—offers clear answers to accelerate new, needed therapies.